 On the other hand, RCTs can be regarded as “debiasing procedure” because they prevent researchers from allocating treatments to patients according to their personal interests, so that the healthiest (or smartest or…) subjects get the researcher’s favorite therapy. While unbalanced allocations can certainly happen by chance, randomization still provides some warrant that the allocation was not done on purpose with a view to promoting somebody’s interests. A priori, the experimental procedure is thus more impartial with respect to the interests at stake. It has thus been argued that RCTs in medicine, while no guarantor of the best outcomes, were adopted by the U.S. Food and Drugs Administration (FDA) to different degrees during the 1960s and 1970s in order to regain public trust in its decisions about treatments, which it had lost due to the thalidomide and other scandals (Teira and Reiss 2013; Teira 2010). It is important to notice, however, that randomization is at best effective with respect to one kind of bias, viz. selection bias. Important other epistemic concerns are not addressed by the procedure but should not be ignored (Worrall 2002).